Novavax Operating Income vs Gross Profit Analysis

NVAX Stock  USD 4.93  0.22  4.67%   
Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Operating Income and its Gross Profit accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Operating Income vs Gross Profit

Operating Income vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Operating Income account and Gross Profit. At this time, the significance of the direction appears to have pay attention.
The correlation between Novavax's Operating Income and Gross Profit is -0.83. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Operating Income and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Novavax are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Operating Income i.e., Novavax's Operating Income and Gross Profit go up and down completely randomly.

Correlation Coefficient

-0.83
Relationship DirectionNegative 
Relationship StrengthSignificant

Operating Income

Operating Income is the amount of profit realized from Novavax operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Novavax is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Novavax minus its cost of goods sold. It is profit before Novavax operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.
Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).

Novavax fundamental ratios Correlations

0.780.94-0.560.87-0.87-0.910.930.940.90.940.940.930.80.940.960.860.990.880.78-0.460.71-0.410.67-0.370.33
0.780.9-0.890.91-0.66-0.90.930.720.880.750.680.840.550.850.90.910.70.550.66-0.350.53-0.320.34-0.260.02
0.940.9-0.750.86-0.88-0.920.960.940.870.930.920.880.830.890.980.860.920.760.67-0.40.68-0.410.55-0.360.21
-0.56-0.89-0.75-0.740.40.79-0.72-0.53-0.71-0.63-0.45-0.69-0.4-0.69-0.76-0.75-0.48-0.4-0.620.35-0.560.21-0.060.15-0.19
0.870.910.86-0.74-0.62-0.960.910.70.990.770.690.970.460.960.921.00.780.740.87-0.430.56-0.360.46-0.30.14
-0.87-0.66-0.880.4-0.620.67-0.82-0.94-0.65-0.87-0.94-0.67-0.9-0.68-0.8-0.61-0.91-0.74-0.380.22-0.450.47-0.60.46-0.03
-0.91-0.9-0.920.79-0.960.67-0.93-0.8-0.97-0.86-0.77-0.98-0.6-0.99-0.97-0.96-0.85-0.77-0.890.5-0.720.34-0.480.28-0.33
0.930.930.96-0.720.91-0.82-0.930.890.910.830.880.90.740.920.960.910.890.680.7-0.410.67-0.40.65-0.360.17
0.940.720.94-0.530.7-0.94-0.80.890.730.920.990.770.950.80.90.690.970.760.57-0.40.73-0.410.71-0.390.34
0.90.880.87-0.710.99-0.65-0.970.910.730.810.720.990.490.980.930.990.820.790.89-0.440.59-0.350.47-0.290.19
0.940.750.93-0.630.77-0.87-0.860.830.920.810.90.850.820.860.940.770.940.90.71-0.430.66-0.440.45-0.410.35
0.940.680.92-0.450.69-0.94-0.770.880.990.720.90.760.940.790.880.670.980.770.55-0.410.7-0.40.74-0.380.32
0.930.840.88-0.690.97-0.67-0.980.90.770.990.850.760.550.990.950.970.860.840.92-0.480.65-0.390.5-0.340.29
0.80.550.83-0.40.46-0.9-0.60.740.950.490.820.940.550.590.750.450.870.610.33-0.320.68-0.360.67-0.360.34
0.940.850.89-0.690.96-0.68-0.990.920.80.980.860.790.990.590.960.960.870.820.91-0.50.7-0.340.54-0.280.33
0.960.90.98-0.760.92-0.8-0.970.960.90.930.940.880.950.750.960.920.920.820.81-0.470.73-0.390.54-0.340.32
0.860.910.86-0.751.0-0.61-0.960.910.690.990.770.670.970.450.960.920.770.730.87-0.420.55-0.360.43-0.290.13
0.990.70.92-0.480.78-0.91-0.850.890.970.820.940.980.860.870.870.920.770.870.7-0.450.71-0.410.72-0.380.36
0.880.550.76-0.40.74-0.74-0.770.680.760.790.90.770.840.610.820.820.730.870.77-0.380.49-0.460.41-0.430.31
0.780.660.67-0.620.87-0.38-0.890.70.570.890.710.550.920.330.910.810.870.70.77-0.550.7-0.240.39-0.180.52
-0.46-0.35-0.40.35-0.430.220.5-0.41-0.4-0.44-0.43-0.41-0.48-0.32-0.5-0.47-0.42-0.45-0.38-0.55-0.590.11-0.320.08-0.53
0.710.530.68-0.560.56-0.45-0.720.670.730.590.660.70.650.680.70.730.550.710.490.7-0.59-0.120.65-0.10.82
-0.41-0.32-0.410.21-0.360.470.34-0.4-0.41-0.35-0.44-0.4-0.39-0.36-0.34-0.39-0.36-0.41-0.46-0.240.11-0.12-0.340.990.09
0.670.340.55-0.060.46-0.6-0.480.650.710.470.450.740.50.670.540.540.430.720.410.39-0.320.65-0.34-0.340.37
-0.37-0.26-0.360.15-0.30.460.28-0.36-0.39-0.29-0.41-0.38-0.34-0.36-0.28-0.34-0.29-0.38-0.43-0.180.08-0.10.99-0.340.09
0.330.020.21-0.190.14-0.03-0.330.170.340.190.350.320.290.340.330.320.130.360.310.52-0.530.820.090.370.09
Click cells to compare fundamentals

Novavax Account Relationship Matchups

Novavax fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets173.0M1.6B2.6B2.3B1.9B1.9B
Other Current Liab19.9M(327.6M)709.8M1.5B1.2B1.3B
Total Current Liabilities25.8M322.0M2.4B2.5B1.6B1.7B
Total Stockholder Equity(186.0M)627.2M(351.7M)(634.1M)(716.9M)(681.1M)
Property Plant And Equipment Net11.4M180.0M228.7M400.5M491.0M515.5M
Net Debt243.1M(231.4M)(1.1B)(787.1M)(298.3M)(283.4M)
Retained Earnings(1.4B)(1.9B)(3.6B)(4.3B)(4.8B)(4.6B)
Accounts Payable2.9M54.3M127.1M216.5M132.6M139.2M
Cash78.8M553.4M1.5B1.3B578.9M607.9M
Non Current Assets Total75.7M334.3M421.6M555.3M711.5M747.0M
Non Currrent Assets Other7.5M13.2M56.7M28.5M30.3M31.8M
Cash And Short Term Investments78.8M711.0M1.5B1.3B578.9M607.9M
Common Stock Shares Outstanding24.1M57.6M74.4M78.2M100.8M105.8M
Liabilities And Stockholders Equity173.0M1.6B2.6B2.3B1.9B1.9B
Other Current Assets93.9M441.8M2.1B1.7B226.0M191.7M
Other Stockholder Equity1.3B2.5B3.3B3.6B4.1B4.3B
Total Liab359.0M955.3M2.9B2.9B2.6B2.7B
Property Plant And Equipment Gross11.4M180.0M258.6M447.8M566.0M594.3M
Total Current Assets97.2M1.2B2.2B1.7B1.1B1.2B
Accumulated Other Comprehensive Income(12.5M)7.0M(1.4M)(6.4M)2.7M2.9M
Net Receivables7.5M262.0M455.0M82.4M297.2M312.1M
Non Current Liabilities Total333.2M633.2M538.1M432.8M937.1M984.0M
Intangible Assets6.5M5.6M5.7M4.8M4.3M4.1M
Short Long Term Debt Total321.9M322.0M454.0M549.8M280.6M294.7M
Common Stock Total Equity3.8M324K714K764K878.6K1.3M
Short Term Debt1.3M322.0M130.5M352.1M28.1M43.9M
Common Stock324K714K764K868K1.4M1.3M
Long Term Debt320.6M322.0M323.5M166.5M168.0M114.6M
Inventory(83.0M)(166.7M)(2.0B)36.7M41.7M43.8M
Property Plant Equipment11.4M180.0M228.7M400.5M460.6M483.6M
Other Liab2.6M3.4M175.5M185.0M212.8M223.4M
Current Deferred Revenue1.7M273.2M1.4B370.1M241.3M140.2M
Other Assets1.1M5.4M16.6M28.5M32.7M34.4M
Good Will51.2M135.4M131.5M126.3M127.5M133.8M
Net Tangible Assets(242.8M)486.1M(487.9M)(760.4M)(684.4M)(650.1M)
Retained Earnings Total Equity(1.3B)(1.4B)(1.9B)(3.6B)(3.3B)(3.1B)
Long Term Debt Total319.2M320.6M322.0M323.5M372.0M234.9M
Capital Surpluse1.1B1.3B2.5B3.4B3.9B4.0B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bonds Directory
Find actively traded corporate debentures issued by US companies
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.41)
Revenue Per Share
9.762
Quarterly Revenue Growth
(0.18)
Return On Assets
(0.17)
Return On Equity
(8.98)
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.